Want to join the conversation?
$ILMN said microarray revenue grew 1% in 1Q16 versus 1Q15 to almost $90MM and orders exceeded the company's expectations with growth of 85%. Shipments to clinical customers grew approx. 20% in 1Q16. NIPT shipments grew 10% or 28% after adjusting for the shift versus the prior year.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.